Familial myeloma and monoclonal gammopathy: A report of eight African American families

American Journal of Hematology

Volumn 84, Issue 1, 2009, Pages 34-38

  Jain, Maneesh ^a   Ascensao, Joao ^a,b   Schechter, Geraldine P ^a,b,c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; AMYLOIDOSIS; ARTICLE; CANCER DIAGNOSIS; CHILD PARENT RELATION; COMORBIDITY; FAMILY HISTORY; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MOTHER; MULTIPLE MYELOMA; MYELOPROLIFERATIVE DISORDER; NEOPLASM; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; RELATIVE; SAMPLE SIZE; SIBLING;

ADULT; AFRICAN AMERICANS; AGED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHIES, BENIGN; MULTIPLE MYELOMA; PEDIGREE;

EID: 58149461564     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21325     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2008;134:573-589.
3. Ries LAG, Melbert D, Krapcho M, et al, editors. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute. Available at:http://seer.cancer.gov/csr/1975-2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.
4. Schechter GP Shoff N, Chan C, et al. The frequency of monoclonal gammopathy of unknown significance in Black and Caucasian veterans in a hospital population. In: Obrams GI,Potter M, editors. Epidemiology and Biology of Multiple Myeloma. New York: Springer; 1991. pp 83-85.
5. Cohen HJ, Crawford J, Rao MK, et al. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med 1998;104:439-444.
6. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006;107: 904-906.
7. Pottern LM, Gart JJ, Nam JM, et al. HLA and multiple myeloma among black and white men: Evidence of a genetic association. Cancer Epidemiol Biomarkers Prev 1992;1:177-182.
8. Brown LM, Linet MS, Greenberg RS, et al. Multiple myeloma and family history of cancer among blacks and whites in the US. Cancer 1999;85:2385-2390.
9. Alexander DD, Mink PJ, Adami H, et al. Multiple myeloma: A review of the epidemiologic literature. Int J Cancer 2007;120:40-61.
10. Morgan GJ, Davies FE, Linet M. Myeloma etiology and epidemiology. Biomed Pharmacotherapy 2002;56:223-234.
11. Zawadzki ZA, Aizawa Y, Kraj MA, et al. Familial immunopathies: Report of nine families and survey of literature. Cancer 1977;40:2094-2101.
12. Shoenfeld Y, Berliner S, Shaklai M, et al. Familial multiple myeloma. A review of thirty-seven families. Postgrad Med J 1982;58:12-18.
13. Horwitz LJ, Levy RN, Rosner F. Multiple myeloma in three siblings. Arch Intern Med 1985;145:1449-1450.
14. Deshpande HA, Hu XP Marino P, et al. Anticipation in familial plasma cell dyscrasias. Br J Haematol 1998;103:896-703.
15. Grosbois B, Jego P. Attal M, et al. Familial multiple myeloma: Report of fifteen families. Br J Haematol 1999;105:768-770.
16. Lynch HT, Watson P, Tarantolo S, et al. Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol 2005;23:685-693.
17. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007:356:2582-2590.
18. Altieri A. Chen B. Bermejo JL, et al. Familial risks and temporal incidence trends of multiple myeloma. Eur J Cancer 2006;42:1661-1670.
19. Sobol H, Vey N, Sauvan R, et al. Re: Familial multiple myeloma: A family study and review of the literature. J Natl Cancer Inst 2002;94:461-462.
20. Ries LAG, Eisner MP, Kosary CL, et al, editors. SEER cancer statistics review, 1975-2000. Available at:http://seer.cancer.gov/csr/1975-2000, 2003.
21. Landgren O, Linet MS, McMaster ML, et al. Familial characteristics of autoimmune and hematologic disorders in 8406 multiple myeloma patients: A population-based case-control study. Int J Cancer 2006;118:3095-3098.
22. Lynch HT, Sanger WG, Pirruccello S, et al. Familial multiple myeloma: A family study and review of the literature. J Natl Cancer Inst 2001;1993:1479-1483.
23. Eriksson M, Hallberg B. Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: A case-control study. Cancer Causes Control 1992;3:83-67.
24. Pasqualetti P, Casale R. Risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Biomed Pharmacother 1997;51:74-78.
25. Kyle RA. "Benign" monoclonal gammopathy: After 20 to 35 years of followup. Mayo Clin Proc 1993;68:26-36.
26. Blade J, Lopez-Guillermo A, Rozman C, et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol 1992;81:391-394.
27. Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 2008;111:3388-3394.
28. Lynch HT, Ferrara K, Barlogie B, et al. Familial myeloma. N Engl J Med 2008;359:152-156.